EcoDrugPlus

Akt Serine/threonine Kinase 2

Ensembl ID : ENSCLAG00000001177
Gene Symbol: AKT2
3 Cross references
252 Possible Orthologues:

Akt Serine/threonine Kinase 3

Ensembl ID : ENSCLAG00000009649
Gene Symbol: AKT3
1 Cross references
199 Possible Orthologues:

Alk Receptor Tyrosine Kinase

Ensembl ID : ENSCLAG00000007813
Gene Symbol: ALK
2 Cross references
195 Possible Orthologues:

Atp Binding Cassette Subfamily B Member 1

Ensembl ID : ENSCLAG00000005038
Gene Symbol: ABCB1
1 Cross references
153 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 1

Ensembl ID : ENSCLAG00000012896
Gene Symbol: ABCC1
2 Cross references
203 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 8

Ensembl ID : ENSCLAG00000017273
Gene Symbol: ABCC8
3 Cross references
245 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 9

Ensembl ID : ENSCLAG00000017154
Gene Symbol: ABCC9
3 Cross references
233 Possible Orthologues:

Atpase H+/k+ Transporting Subunit Alpha

Ensembl ID : ENSCLAG00000013870
Gene Symbol: ATP4A
3 Cross references
183 Possible Orthologues:

Atpase H+/k+ Transporting Subunit Beta

Ensembl ID : ENSCLAG00000003301
Gene Symbol: ATP4B
3 Cross references
171 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Alpha 1

Ensembl ID : ENSCLAG00000005733
Gene Symbol: ATP1A1
2 Cross references
328 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Alpha 2

Ensembl ID : ENSCLAG00000012804
Gene Symbol: ATP1A2
2 Cross references
207 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Alpha 3

Ensembl ID : ENSCLAG00000001351
Gene Symbol: ATP1A3
2 Cross references
134 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).